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The AFFIRM Study: Approaches
to Control Rate in Atrial Fibrillation
The optimal heart rate for patients with atrial fibrillation (AF)
remains unclear; current guidelines are primarily based on clinical
experience (1). Recent randomized studies suggest combining
beta-blockers or calcium channel blockers with digoxin to achieve
better rate control at rest and during exercise (2–4). However, I
believe clarification of the “approach to control rate in AF” by the
Atrial Fibrillation Follow-up Investigation of Rhythm Manage-
ment (AFFIRM) investigators (4) is justified.
A total of 2,027 patients were randomized to the rate control
arm of the AFFIRM trial between 1995 and 1999. Of these, 248
crossed over to the rhythm-control group due to “uncontrolled
symptoms” and 108 underwent AV nodal ablation due to failure of
pharmacologic therapy. Rate-control data at rest are available in
only 740 (36.5%) patients, which deteriorates further to 361
(17.8%) if data regarding heart-rate control during exercise are
desired.
This relative lack of data may be explained by the fact that 1,055
(52%) patients were in sinus rhythm at the time of randomization.
The proportion of those in the rate-control group who maintained
sinus rhythm during follow-up is unclear. Published data for the
entire trial population suggest a similar number (49%) remaining
in sinus rhythm at study end.
Therefore, the majority of data on rate control of AF comes
from a minority of patients randomized to a rate-control strategy.
Because of the nature of data collection (only patients with AF at
the time of assessment were selected for analysis), care should be
taken in interpreting these results. The data predominantly repre-
sent patients with persistent and permanent AF and significantly
underrepresent those with paroxysmal AF.
It is difficult to make conclusions on the control of ventricular
rate during paroxysms of AF from this study, the occurrence of
which greatly depends on variations of the autonomic tone (5).
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REPLY
We thank Dr. Van Gelder and colleagues and Dr. Shelton for their
interest in our study (1). We agree with Dr. Van Gelder and
colleagues that the optimal heart rate in atrial fibrillation (AF)
during rest and exercise is unknown. Perhaps minimal effort to
achieve rate control during AF is sufficient. However, absence of
adequate rate control can lead to adverse consequences such as
tachycardia-induced cardiomyopathy. Our Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
substudy was not designed to evaluate the mortality and morbidity
of inadequate rate control; thus, we cannot comment on these end
points.
Both ablation of the atrioventricular junction and pacemaker
insertion were allowed “innovative” therapies in the AFFIRM
study, and they may have contributed to the relatively frequent use
of this approach. Furthermore, attempting to achieve more “strin-
gent” rate control may have led to more symptomatic drug-induced
bradycardia and subsequent pacemaker insertion in the AFFIRM
study, compared to the more “lenient” criteria used in the RAte
Control versus Electrical cardioversion (RACE) study. However,
the patient population in the AFFIRM study was not directly
comparable to that in RACE, and pacemaker implantation per
capita in the U.S. is higher than in Europe. These factors may have
influenced the differences between these two studies.
We agree that a long-term, prospective, randomized trial would
be useful. We applaud Dr. Van Gelder and colleagues for pursuing
answers to some of these difficult issues in the RAte Control
Efficacy in permanent atrial fibrillation (RACE II) study.
Dr. Shelton concurs that the optimal approach to rate control
remains primarily based on clinical experience. He notes that 248
patients in the AFFIRM study crossed over to the rhythm-control
group, and 108 patients underwent ablation of the atrioventricular
junction (1). Many patients (approximately one-half) in the
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